Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Dental equipment & supplies
Sub-IndustryN/A
SectorMedical
Phone949-645-2111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.56 million
Profitability
Miscellaneous
Employees39
OptionableNot Optionable
Biomerica (NASDAQ:BMRA) Frequently Asked Questions
What is Biomerica's stock symbol?
Biomerica trades on the NASDAQ under the ticker symbol "BMRA."
How were Biomerica's earnings last quarter?
Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings results on Tuesday, January, 15th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.51 million. Biomerica had a negative return on equity of 45.72% and a negative net margin of 36.36%. View Biomerica's Earnings History.
When is Biomerica's next earnings date?
What price target have analysts set for BMRA?
1 Wall Street analysts have issued twelve-month target prices for Biomerica's shares. Their predictions range from $6.25 to $6.25. On average, they expect Biomerica's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 147.0% from the stock's current price. View Analyst Price Targets for Biomerica.
What is the consensus analysts' recommendation for Biomerica?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biomerica.
Has Biomerica been receiving favorable news coverage?
News coverage about BMRA stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biomerica earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Biomerica's key competitors?
Who are Biomerica's key executives?
Biomerica's management team includes the folowing people:
- Mr. Zackary S. Irani, Chairman & CEO (Age 53)
- Mr. Francis E. Capitanio, Pres (Age 75)
- Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68)
Who are Biomerica's major shareholders?
Biomerica's stock is owned by many different of institutional and retail investors. Top institutional investors include Perritt Capital Management Inc. (0.43%). Company insiders that own Biomerica stock include Francis Cano, Francis E Capitanio and Zackary S Irani. View Institutional Ownership Trends for Biomerica.
Which institutional investors are buying Biomerica stock?
BMRA stock was purchased by a variety of institutional investors in the last quarter, including Perritt Capital Management Inc.. Company insiders that have bought Biomerica stock in the last two years include Francis Cano and Zackary S Irani. View Insider Buying and Selling for Biomerica.
How do I buy shares of Biomerica?
Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biomerica's stock price today?
One share of BMRA stock can currently be purchased for approximately $2.53.
How big of a company is Biomerica?
Biomerica has a market capitalization of $23.59 million and generates $5.56 million in revenue each year. The company earns $-1,460,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Biomerica employs 39 workers across the globe.
What is Biomerica's official website?
How can I contact Biomerica?
Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111.
MarketBeat Community Rating for Biomerica (NASDAQ BMRA)
MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote "Outperform" if you believe BMRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
